Data presented at ASCO GI for Keytruda in esophageal cancers

Merck & Co. Inc. (NYSE:MRK) reported detailed data on Jan. 14 from the Phase III KEYNOTE-181 trial showing that Keytruda pembrolizumab monotherapy as second-line treatment for advanced or metastatic esophageal or esophagogastric junction carcinoma

Read the full 341 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE